Why Mineralys Therapeutics, Inc. (MLYS) stock fell 14.4% on Friday, October 30, 2026

Mineralys Therapeutics, Inc. (MLYS) closed at $18.18, down 14.41% on Friday, October 30, 2026, on volume of 3,967,198 shares (3.2× its 3-month average); market value about $1.60B.

What happened: primary sources

Events Nexqual found for MLYS on Friday, October 30, 2026 or the trading day before (October 29, 2026):

• Oct 29, 2026: SEC 8-K: Entered a material agreement; Ended a material agreement source
  Quoted from the filing: “Mineralys Therapeutics, Inc. (the Company) and Tanabe Pharma Corporation (Tanabe) were previously parties to that certain License Agreement, dated July 9, 2020 and amended on November 24, 2020, June 15, 2023, May 29, 2025 and June 2, 2026 (as amended, the License Agreement), pursuant to which Tanabe had granted to the Company an exclusive, worldwide, royalty-free, sublicensable, perpetual and irrevocable license to certain intellectual property rights to develop and commercialize lorundrostat. Under the License…”

These are listed as context. A filing or rating change on the same day is not proof that it caused the move; read the source.

More on MLYS

MLYS stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. Other big moves that day: October 30, 2026.

Sources: SEC EDGAR, Nexqual Earnings Flash, analyst rating changes, Nexqual market data. Built November 4, 2026 at 11:37 UTC. Not investment advice.

Data source: Nexqual. Last updated: November 4, 2026 at 11:37 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt